Demant A/S

Equities

DEMANT

DK0060738599

Medical Equipment, Supplies & Distribution

Market Closed - Nasdaq Copenhagen Other stock markets 10:59:47 2024-04-19 am EDT			5-day change	1st Jan Change
315.6 ^DKK	+1.48%		-4.83%	+6.62%

Apr. 08	Denmark's Demant Finalizes Capital Reduction	MT
Apr. 04	Competition Regulator Clears Cochlear’s Acquisition of Oticon Medical’s Cochlear Implant Business	MT

Demant A/S: Investor news - comparative figures for 2021

August 12, 2022 at 12:33 pm EDT

12.8.2022 18:32:54 CEST | Demant A/S | Investor News

Investor news

12 August 2022

Comparative figures for 2021

On 27 April 2022, Demant announced the decision to discontinue its Hearing Implants business. In accordance with IFRS 5 – Non-current Assets Held for Sale and Discontinued Operations and as previously communicated, Hearing Implants is therefore recognised in the Group’s financial reporting and statements as a discontinued operation, and comparative figures for 2021 are restated to reflect this. To help reconcile such restated figures with reported figures, we attach restated income statements (unaudited) for the following reporting periods: H1 2021, H2 2021 and FY 2021.

Please note that the attachment only includes historical figures in order to ease the comparison between historical and future performance.

Further information:

Søren Nielsen, President & CEO

Phone +45 3917 7300

www.demant.com

Other contacts:

René Schneider, CFO

Mathias Holten Møller, Head of Investor Relations

Peter Pudselykke, Investor Relations Officer

Trine Kromann-Mikkelsen, VP Corporate Communication and Relations

About Demant A/S

Demant is a world-leading hearing healthcare group that offers solutions and services to help people with hearing loss connect with the world around them. In every aspect, from hearing devices, hearing implants, diagnostics to audio and video solutions and hearing care all over the world, Demant is active and engaged. Our innovative technologies and know-how help improve people’s health and hear-ing. We create life-changing differences through hearing health.

Attachments

220812 Investor news - comparative figures for 2021.pdf
Demant - Comparative figures for 2021.xlsx

Latest news about Demant A/S

Denmark's Demant Finalizes Capital Reduction	Apr. 08	MT
Competition Regulator Clears Cochlear’s Acquisition of Oticon Medical’s Cochlear Implant Business	Apr. 03	MT
Demant Seeks Acquisitions	Mar. 12	CI
Transcript : Demant A/S - Analyst/Investor Day	Mar. 12
Nordic Stocks Closed Down Wednesday; Electrolux Series a Posted Biggest Loss	Feb. 28	DJ
Anja Madsen Announces Not to Stand for Re-Election to the Board of Directors of Demant A/S	Feb. 07	CI
Nordic Shares Rose Tuesday; Demant Climbed Highest	Feb. 06	DJ
DEMANT : In-line Q4; markets cheer the promising takeaways for 2024	Feb. 06
Global markets live: BP, Palantir, Infineon, Toyota, UBS...	Feb. 06
Transcript : Demant A/S, 2023 Earnings Call, Feb 06, 2024	Feb. 06
US Futures Mixed, European Stocks Rise as Investors Parse More Fedspeak	Feb. 06	DJ
Tranche Update on Demant A/S's Equity Buyback Plan announced on March 5, 2021.	Feb. 06	CI
Demant A/S Reports Earnings Results for the Full Year Ended December 31, 2023	Feb. 06	CI
Demant Forecasts Up to 8% Organic Revenue Growth in FY24	Feb. 06	MT
Demant to Explore Strategic Options for Communications Business Amid Weak Market Conditions	Feb. 05	MT
Demant A/S Provides Earnings Guidance for the Year 2024	Feb. 05	CI
Demant A/S Promotes Peter Pudselykke as Head of Investor Relations Effective 1 March 2024	Jan. 03	CI
Demant to Recommence Share Buybacks	Nov. 21	MT
Nordic Stocks Dropped Tuesday; Demant Took Biggest Hit	Nov. 07	DJ
DEMANT : Sales broadly in-line; guidance narrowed	Nov. 07
Transcript : Demant A/S, Q3 2023 Interim Management Statement Call, Nov 07, 2023	Nov. 07
US Futures Slip, European Stocks Mostly Flat	Nov. 07	DJ
Demant Q3 revenue meets forecast, narrows outlook	Nov. 07	RE
Demant A/S Provides Earnings Guidance for the Year 2023	Nov. 07	CI
European Commission OKs Cochlear's Aquisition of Oticon Medical Unit	23-10-10	MT

Chart Demant A/S

Duration

Period

More charts

Company Profile

Demant A/S is the world's 2nd leading producer of audio products. Net sales (excluding activities held for sale) break down by family of products as follows: - tailor-made hearing aids (44.7%): hearing aid and audiphones sold under the Oticon, Bernafon, Philips and Sonic brands; - hearing care products (40.5%): sold in clinics under the brands Audika, HearingLife, Hidden Hearing and Acústica Médica; - diagnostic products (1116%): audiometers sold under the brands Maico, Interacoustics, amplivox, gsi, MedRx and audioscan; - business communication solutions (3.7%). Net sales (excluding activities held for sale) are distributed geographically as follows: Denmark (1.2%), France (9.9%), Europe (29.7%), the United States (34.1%), North America (7%), Asia (10.4%), Pacific (4.9%) and other (2.8%).

Sector

Medical Equipment, Supplies & Distribution

Calendar

2024-05-05 - Q1 2024 Sales and Revenue Release - Interim Management Statement

Related indices

STOXX EUROPE 600 (EUR)

More about the company

Income Statement Evolution

More financial data

Analysis / Opinion

DEMANT : In-line Q4; markets cheer the promising takeaways for 2024

February 06, 2024 at 12:46 pm EST

More Strategies

Ratings for Demant A/S

Trading Rating

Investor Rating

ESG Refinitiv

B-

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

HOLD

Number of Analysts

Last Close Price

311 DKK

Average target price

334.1 DKK

Spread / Average Target

+7.44%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Medical Prosthetics

	1st Jan change	Capi.
DEMANT A/S	+6.62%	9.68B
STRAUMANN HOLDING AG	-1.84%	23.52B
SONOVA HOLDING AG	-9.62%	16.27B
COCHLEAR LIMITED	+5.69%	13.45B
EYEBRIGHT MEDICAL TECHNOLOGY (BEIJING) CO., LTD.	-21.76%	2.01B
EMBLA MEDICAL HF.	+12.20%	1.8B
ANGELALIGN TECHNOLOGY INC.	+30.15%	1.62B
MODERN DENTAL GROUP LIMITED	+8.37%	570M
ANGEL ROBOTICS CO., LTD.	0.00%	524M
INTEGRUM AB	+29.68%	96.53M

Medical Prosthetics